Argos Therapeutics Inc.: Argos Therapeutics to Hold Fourth Quarter and Year End 2013 Financial Results Conference Call on Thursday, March 27, 2014

Tickers: ARGS
DURHAM, N.C., March 14, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 27, 2014. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 8194260. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is in a pivotal Phase 3 trial for the treatment of mRCC, and the company plans to have data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid- 2014.Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Jeffrey Abbey

         President & Chief Executive Officer

         Argos Therapeutics

         jabbey@argostherapeutics.com

         (919) 287-6308


         Media:

         Andrea Coan

         Berry & Company Public Relations

         acoan@berrypr.com

         (212) 253-8881


         Investors:

         Angeli Kolhatkar

         Burns McClellan

         akolhatkar@burnsmc.com

         (212) 213-0006
Source: Argos Therapeutics, Inc. News Provided by Acquire Media

distributed by

This noodl was issued by Argos Therapeutics Inc. and was initially posted at www.argostherapeutics.com. It was distributed, unedited and unaltered, by noodls on 2014-03-14 22:19:57 CET. The issuer is solely responsible for the accuracy of the information contained therein.